Wednesday, May 5, 2021 Short-Course TB Treatment: Landmark Trial Results Published in Peer-Reviewed Journal A large international clinical trial has established that a new four-month daily treatment regimen is as safe and effective as the standard six-month daily regimen at curing drug-susceptible tuberculosis disease, researchers report today in the New England Journal of Medicine. Results from the Phase 3 trial, led by the CDC's Tuberculosis Trials Consortium and supported in part by the NIAID-funded AIDS Clinical Trials Group, were first presented in October 2020 at the Union World Conference on Lung Health. A shorter regimen has the potential to increase completion of therapy, improve patient quality of life, reduce treatment costs, and decrease development of drug resistance.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107